Indeed, a clinical trial (DK-301) from our institution evaluating goserelin acetate 10.8-mg depot as first-line ADT in advanced PCa patients (n = 12) showed a gradual decline of PSA/PAP ratio following first-line ADT (Fig. 4d). This evidence concerns the gene KLK3 and posterior cortical atrophy.